Royalty Pharma plc Class A Ordinary Shares (RPRX) — Analysis Summary
Royalty Pharma plc Class A Ordinary Shares (RPRX) has a market cap of $25.90B with year-over-year revenue growth of +5.1%. Net margin stands at 32.4%. The stock trades at a P/E ratio of 31.3.
Key Takeaways
- Revenue changed +5.1% year-over-year
- Net margin of 32.4%
- P/E ratio of 31.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, RPRX posted revenue growth of +5.1% and trades at a P/E of 31.3.
Royalty Pharma plc Class A Ordinary Shares (RPRX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (65.1%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Operating margin at 65.1% — exceptionally high, typical only for monopolistic or IP-heavy businesses
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
100
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.94
Dividend Yield
1.61%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.